medcelerator · clinician one-pager
New Prescription Ointment for Mild-to-Moderate Eczema Ages 2 and Up
Adquey (difamilast) — topical ointment for mild-to-moderate eczema (atopic dermatitis)
FDA Approved · United States · September 22, 2026
Condition: Atopic Dermatitis
Who this is for
This is for people with mild to moderate atopic dermatitis (eczema) — and caregivers of children 2 years and older — who may be candidates for labelled US Adquey ointment. It explains the 12 Feb 2026 FDA approval, how twice-daily topical use works, Week-4 clearance numbers from the label, how Adquey relates to (and is distinct from) older topical PDE4 ointment, and how to ask a dermatologist or paediatrician for a prescription — without treating Adquey as a steroid, confusing it with injectable biologics for severe disease, or importing a US or Japanese tube. Authorised is not funded.
Next clinical step
This is FDA authorised, not Health Canada authorised. Ask the clinician about US care, a trial, or a Special Access Programme path in United States.
Access doors
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
FDA Expanded Access (Patient Affairs)
US Food and Drug Administration path for a licensed clinician to request an investigational medical product for a patient with a serious or immediately life-threatening condition when no comparable approved therapy is available. This is a request path, not a labelled indication. Authorized is not funded.
https://www.fda.gov/news-events/public-health-focus/expanded-access
Not medical advice. Authorized is not funded. Full piece: https://medcelerator.com/articles/adquey-difamilast-atopic-dermatitis